|
MRNA | Moderna, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.94 |
| Leverage | 23.11% |
| Market Cap | $ 9.9B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -3.1B |
| Margin | -140.61% |
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.